A European pilot study in Dravet Syndrome to delineate what really matters for the patients and families.

We aimed to identify caregivers' opinions on the outcome measures that matter in clinical trials in individuals with Dravet syndrome (DS). We conducted a prospective European multicenter study based on an 11 closed questions survey developed by the French reference center for rare epilepsies and DS patients' advocacy groups. Items included questions on seizures and daily life outcomes that a clinical trial on a therapy for individuals with DS should target. Statistical analyses were performed to evaluate the impact of the country of residence and of the patients' age. The survey was answered by 153 caregivers (68%: France, 28%: Germany, and 24%: Italy) off individuals with DS. Individuals with DS included 86 males (mean age of 11.4 [interquartile: 7-20.4] years). Families ranked as important almost all the items proposed. However, items related to daily life had the highest rank in all three countries compared to items about seizures (P = 0.02). Increase in individuals' age was associated with a higher age at diagnosis (ρ = 0.26, P = 0.02), and a lower impact of seizure duration (ρ = -0.25, P = 0.005) and on the need of hospital referral (ρ = -0.26, P = 0.005). These data can help tailor patient-centered outcome measures in future clinical and real-life trials for DS. © 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Citation

Nicole Chemaly, Mathieu Kuchenbuch, Théo Teng, Elodie Marie, Gianluca D'Onofrio, Tommaso Lo Barco, Isabella Brambilla, Silke Flege, Anne-Sophie Hallet, Rima Nabbout. A European pilot study in Dravet Syndrome to delineate what really matters for the patients and families. Epilepsia open. 2024 Feb;9(1):388-396

Mesh Tags

PMID: 34747137

search → result